Abstract 1583P
Background
Surrogate endpoints (SEPs) are intermediate endpoints that can substitute clinical outcomes such as overall survival (OS). Neoadjuvant or adjuvant immune checkpoint blockade (ICB) may improve survival for patients diagnosed with early cancer disease. Multiple studies evaluating the role of ICB in the curative setting leveraged SEPs to predict treatment efficacy, although few studies sought to evaluate the surrogacy performance of these endpoints. Our meta-analysis aims to investigate whether SEPs can predict outcomes for cancer patients treated with ICB in the curative setting.
Methods
We systematically searched Embase, PubMed, and Cochrane databases up to March 2024 for randomized controlled trials (RCTs) assessing ICBs in the adjuvant or neoadjuvant settings. Studies evaluating adult patients with solid tumours were included. Disease-free survival (HR_DFS), 1-year overall survival (HR_1yr), event-free survival (HR_EFS), and complete pathological responses (pCR) were assessed using SEPs for OS (HR_OS). Statistical analysis included linear regression models weighted by trial sizes. SEPs were categorized based on the coefficient of determination (R2) as follows: R2 ≥ 0.7 will be interpreted as strong correlations, values between 0.69 and 0.5 as moderate correlations, and values < 0.5 as weak correlations.
Results
We included 28 out of 3,233 studies, encompassing 18,754 patients treated with ICB in curative settings. HR_DFS revealed a good association with HR_OS (R2 = 0.64; 95% CI, 0.32–0.96), while the HR_1yr demonstrated poor correlation with HR_OS (R2=0.00, 95%CI 0.00-0.03). Similarly, in neoadjuvant ICB (6,938 patients), HR_EFS (R2= 0.34, 95%CI 0.00-0.96) and risk ratio for pCR (R2= 0.04, 95%CI 0.00-0.39) did not exhibit a strong surrogacy performance for HR_OS. Notably, in the subgroup analysis of patients with melanoma, DFS presented a strong correlation with OS (R2= 0.79. 95%CI 0.46-1.00).
Conclusions
Our meta-analysis suggests that SEPs for RCTs evaluating ICB in the curative setting demonstrate limited trial-level surrogacy performance for OS. In studies evaluating adjuvant treatment for pts with melanoma, DFS showed strong surrogacy for OS. Further studies should be conducted to validate the use of SEPs in clinical trial and drug approval process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10